MATTHEW GELLER: Open Payments
NPI 1346317013 · LONG BRANCH, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$826 in 54 payments from 10 companies in 2025. Trend: 2023 $275 · 2024 $90 · 2025 $826
Food & beverage: $826
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $289 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $114 |
| Alkermes, Inc. | 6 | $109 |
| Axsome Therapeutics, Inc. | 5 | $88 |
| Vanda Pharmaceuticals Inc. | 5 | $78 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Braeburn Inc. | 1 | $17 |
Products named: VRAYLAR, CAPLYTA, Auvelity, FANAPT, ARISTADA, UZEDY, LYBALVI, COBENFY.
Industry payments across NJ — which companies pay providers there.
